Role of Innovator Product Characterization in Generic Product Development

Generic drug products are defined as drug products that are comparable to the innovator/reference listed drug products (RLD) in dosage form, strength, route of administration, quality and performance characteristics, and intended use. These products play a critical role in the healthcare systems and contribute to more than 50 % of the total prescriptions by volume. Generic products are accorded regulatory approval based on the concept of therapeutic equivalence to the RLD. Therapeutic equivalence comprises of pharmaceutical equivalence and bioequivalence. Speed to the marketplace is the key for success in generic market. Development of generic products can be accelerated by performing characterization of the RLD, also referred as de-formulation studies. These studies, related to quantification of critical excipients, and solid state characterization of the active pharmaceutical ingredient, could provide critical inputs for formulation development of generic products. This chapter highlights the role of innovator product characterization in accelerating formulation development of generic products. Role of such studies in simplifying regulatory approval process has also been highlighted.

[1]  Stephen R Byrn,et al.  Solid-state analysis of the active pharmaceutical ingredient in drug products. , 2003, Drug discovery today.

[2]  Weiyong. Li,et al.  Quantitation of active pharmaceutical ingredients and excipients in powder blends using designed multivariate calibration models by near-infrared spectroscopy. , 2005, International journal of pharmaceutics.

[3]  G. Brinkmalm,et al.  Development of a size exclusion chromatography method for the determination of molar mass for poloxamers. , 2003, Journal of pharmaceutical and biomedical analysis.

[4]  M. J. Thompson,et al.  Quantitation of poloxamers in pharmaceutical formulations using size exclusion chromatography and colorimetric methods. , 2004, Journal of pharmaceutical and biomedical analysis.

[5]  Robert A. Lionberger,et al.  FDA Critical Path Initiatives: Opportunities for Generic Drug Development , 2008, The AAPS Journal.

[6]  Determination of ascorbic acid in pharmaceutical preparations by near infrared reflectance spectroscopy. , 1993, Talanta.

[7]  A. Hussain,et al.  A Modern View of Excipient Effects on Bioequivalence: Case Study of Sorbitol , 2006, Pharmaceutical Research.

[8]  Bo Chen,et al.  Determination of neotame in beverages, cakes and preserved fruits by column-switching high-performance liquid chromatography , 2010, Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment.

[9]  J. Irache,et al.  An HPLC with evaporative light scattering detection method for the quantification of PEGs and Gantrez in PEGylated nanoparticles. , 2007, Journal of pharmaceutical and biomedical analysis.

[10]  Christopher A. Mattson,et al.  A Generic Formulaic Characterization of the Time to Reverse Engineer the Tolerances of a Product , 2009 .

[11]  J. Coello,et al.  Quantitation of the active compound and major excipients in a pharmaceutical formulation by near infrared diffuse reflectance spectroscopy with fibre optical probe , 1996 .

[12]  Lawrence X. Yu,et al.  Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs). , 2004, Advanced drug delivery reviews.

[13]  D. Barends,et al.  Review of global regulations concerning biowaivers for immediate release solid oral dosage forms. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[14]  D M Barends,et al.  Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride. , 2005, Journal of pharmaceutical sciences.

[15]  Vinod P. Shah,et al.  Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions , 2002, Pharmaceutical Research.

[16]  Stephen Byrn,et al.  Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations , 1995, Pharmaceutical Research.

[17]  Christos Reppas,et al.  Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms , 2004, Pharmaceutical Research.

[18]  Gordon L Amidon,et al.  A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.

[19]  K. Khanvilkar,et al.  Effects of Manufacturing Process Variables on In Vitro Dissolution Characteristics of Extended-Release Tablets Formulated with Hydroxypropyl Methylcellulose , 2003, Drug development and industrial pharmacy.

[20]  L. Lesko,et al.  The impact of formulation and process changes on in vitro dissolution and the bioequivalence of piroxicam capsules. , 1998, Pharmaceutical development and technology.

[21]  David E. Bugay,et al.  Physical Characterization of Pharmaceutical Solids , 1995, Pharmaceutical Research.

[22]  Arvind K. Bansal,et al.  The role of reverse engineering in the development of generic formulations , 2005 .

[23]  D. Crommelin,et al.  1H NMR Quantification of poly(Ethylene Glycol)-Phosphatidylethanolamine in Phospholipid Mixtures , 1999, Pharmaceutical Research.

[24]  R. Strickley,et al.  Drug-Excipient Incompatibility Studies of the Dipeptide Angiotensin-Converting Enzyme Inhibitor, Moexipril Hydrochloride: Dry Powder vs Wet Granulation , 1990, Pharmaceutical Research.

[25]  Shiew-Mei Huang,et al.  Bioavailability and Bioequivalence: An FDA Regulatory Overview , 2001, Pharmaceutical Research.

[26]  H. Kristensen,et al.  Quantitative analysis of povidone (PVP) in drug-PVP matrix using multicomponent analysis. , 1999, Drug development and industrial pharmacy.

[27]  M. Gj Overview of the Hatch-Waxman Act and its impact on the drug development process. , 1999 .

[28]  P. Desbène,et al.  Quantitative trace analysis of surfactant mixtures by reversed-phase high-performance liquid chromatography with refractometric detection , 1996 .

[29]  Mario Aranda,et al.  Routine Method for Quantification of Starch by Planar Chromatography (HPTLC) , 2005, JPC – Journal of Planar Chromatography – Modern TLC.

[30]  C. Vogt,et al.  Separation of nonionic surfactants by capillary electrophoresis and high-performance liquid chromatography. , 1998, Analytical chemistry.

[31]  P. York Solid-state properties of powders in the formulation and processing of solid dosage forms , 1983 .

[32]  Arvind K. Bansal,et al.  Comprehensive Characterisation of the Innovator Product: Targeting Bioequivalent Generics , 2005 .